RESEARCH PAPER
Urban and rural differences in ovarian cancer patients’ characteristics
More details
Hide details
1
Division of Gynecological Surgery, University of Medical Sciences, Poznan, Poland
Ann Agric Environ Med. 2013;20(2):390-394
KEYWORDS
ABSTRACT
Introduction and objective. The aim of the study was evaluation of the urban and rural differences in ovarian cancer patients’ characteristics at the moment of diagnosis.
Materials and methods. The study comprised women with ovarian cancer diagnosed and treated in the Division of Gynecological Surgery of Poznan University of Medical Sciences between 2004–2011. The patients were divided into 3 groups based on their place of residence: 1) patients residing in large cities (over 50,000 people), 2) inhabitants of small towns (below 50,000 people), 3) women from rural areas.
Results. Among the studied groups of patients no differences were found in the FIGO stage at diagnosis (p=0.453), histological grade of the tumour (p=0.916), histopathological types of ovarian neoplasms (p=0.431), median tumour volume (p=0.855), presence of fluid in the pouch of Douglas (p=0.872). Women with ovarian cancer residing in large cities had lower median parity (p=0.0005), higher education level status (p=0.0001), and experienced menarche at an earlier age (p=0.039). There were no differences in the use of oral contraception (p=0.93) and body mass index (p=0.23) between the women included in the study.
Conclusions. There were no differences in advancement of ovarian cancer at the moment of diagnosis or in tumour type and size between women residing large cities, small towns and rural areas. Several ovarian cancer risk factors were more common among ovarian cancer patients living in urbanized areas.
REFERENCES (34)
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225–249.
2.
du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol. 2009; 112: 422–436.
3.
Dey S, Hablas A, Seifeldin IA, Ismail K, Ramadan M, El-Hamzawy H, et al. Urban-rural differences of gynaecological malignancies in Egypt (1999–2002). BJOG 2010; 117: 348–355.
4.
Krzyzak M, Maslach D, Bielska-Lasota M, Juczewska M, Rabczenko D, Marcinkowski JT, et al. Breast cancer survival gap between urban and rural female population in Podlaskie Voivodship, Poland, in 2001–2002. Population study. Ann Agric Environ Med. 2010; 17: 277–282.
5.
Krzyzak M, Maslach D, Juczewska M, Lasota W, Rabczenko D, Marcinkowski J, et al. Differences in breast cancer incidence and stage distribution between urban and rural female population in Podlaskie Voivodship, Poland in years 2001–2002. Ann Agric Environ Med. 2010; 17: 159–162.
6.
Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009; 105: 3–4.
7.
Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol. 2000; 16: 500–505.
9.
Berek JS FM, Hacker NF. Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. In: Berek and Hacker’s Gynecologic Oncology, 5th Ed. Philadelphia: Lippincott Williams & Wilkins; 2009. pp. 443–508.
10.
Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10: 327–340.
11.
Timmerman D, Schwarzler P, Collins WP, Claerhout F, Coenen M, Amant F, et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol. 1999; 13: 11–16.
12.
Vergote I, Amant F, Ameye L, Timmerman D. Screening for ovarian carcinoma: not quite there yet. Lancet Oncol. 2009; 10: 308–309.
13.
Parkin DM WS, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. In. Lyon: International Agency for Research on Cancer; 2002.
14.
Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J. Rural and urban differences in stage at diagnosis of colorectal and lung cancers. Br J Cancer. 2001; 84: 910–914.
15.
Singh GK. Rural-urban trends and patterns in cervical cancer mortality, incidence, stage, and survival in the United States, 1950–2008. J Community Health. 2012; 37: 217–223.
16.
Spaczynski M, Nowak-Markwitz E, Kedzia W. Cervical cancer screening in Poland and worldwide. Ginekol Pol. 2007; 78: 354–360 (in Polish).
17.
Bankhead CR, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG 2008; 115: 1008–1014.
18.
Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000; 89: 2068–2075.
19.
Wong ST, Regan S. Patient perspectives on primary health care in rural communities: effects of geography on access, continuity and efficiency. Rural Remote Health 2009; 9: 1142.
20.
Tate AR, Martin AG, Murray-Thomas T, Anderson SR, Cassell JA. Determining the date of diagnosis-is it a simple matter? The impact of different approaches to dating diagnosis on estimates of delayed care for ovarian cancer in UK primary care. BMC Med Res Methodol. 2009; 9: 42.
21.
Chan K. Reducing Delays in Referrals. Cancer Services Collaborative Service Improvement Guide: Ovarian Cancer. London: NHS Modernisation Agency; 2001.
22.
Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 2009; 6: e1000114.
23.
Monroe AC, Ricketts TC, Savitz LA. Cancer in rural versus urban populations: a review. J Rural Health. 1992; 8: 212–220.
24.
Doll R. Urban and rural factors in the aetiology of cancer. Int J Cancer 1991; 47: 803–810.
25.
Minelli L, Stracci F, Cassetti T, Canosa A, Scheibel M, Sapia IE, et al. Urban-rural differences in gynaecological cancer occurrence in a central region of Italy: 1978–1982 and 1998–2002. Eur J Gynaecol Oncol. 2007; 28: 468–472.
26.
Sueblinvong T, Carney ME. Current understanding of risk factors for ovarian cancer. Curr Treat Options Oncol. 2009; 10: 67–81.
27.
Timmerman D, Verrelst H, Bourne TH, De Moor B, Collins WP, Vergote I, et al. Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. Ultrasound Obstet Gynecol. 1999; 13: 17–25.
28.
Brinton LA SM. Epidemiology of gynecologic cancers. In: Principles and Practice of Gynecologic Oncology, 5th Edition. Edited by Barakat RR PR, Markman M, Randall M. Philadelphia: Lippincott Williams & Wilkins; 2009. pp. 3–29.
29.
Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C. Risk factors for epithelial ovarian cancer in women under age 45. Eur J Cancer 1993; 29A: 1297–1301.
30.
Wronka I, Pawlinska-Chmara R. Menarcheal age and socio-economic factors in Poland. Ann Hum Biol. 2005; 32: 630–638.
31.
Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2011; 105: 1436–1442.
32.
Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 2007; 43: 690–709.
33.
Lukanova A, Toniolo P, Lundin E, Micheli A, Akhmedkhanov A, Muti P, et al. Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer 2002; 99: 603–608.
34.
Romundstad P, Janszky I, Vatten L, Hakon Bjorngard J, Langhammer A, Manczuk M, et al. Cancer risk factors in Poland: the PONS Study. Ann Agric Environ Med. 2011; 18: 251-254.